Interestingly, the BRAFi-resistant melanoma with wild-type PTEN has high potential resistance to MEK inhibitor Trametinib with more than 50 higher resistance indexes (RI) [WM88 (IC50 = 0.031 μM)/WM88R (IC50 = 38.87 μM, RI = 1253.8; A375sm (IC50 = 11.38 μM)/A375smR (791.6 μM), RI = 69.56)]. Here, MAP2K7 is linked to melanoma.